Ginkgo Bioworks Holdings: Pay

Ginkgo Bioworks Holdings paid its 4 named executives $10.9M in total in FY2025 (Dec). CEO Jason Kelly was paid $5.7M of that.

PayNo stock prices for these years
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Jason KellyChief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
4 years
Reshma ShettyPresident & Former Chief Operating Officer
FY2025 (Dec)
FY2024 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
4 years
Steven CoenChief Financial Officer
FY2025 (Dec)
1 year
Mark DmytrukFormer Chief Financial Officer
FY2025 (Dec)
FY2024 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
4 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 10 peers with pay on file was $7.8M. CEO pay of Ginkgo Bioworks Holdings for that year is not on file.

  1. 1Twist Bioscience
  2. 2Ultragenyx Pharmaceutical
  3. 3Standard Biotools
  4. 4Travere Therapeutics
  5. 5Vir Biotechnology
  6. 6CRISPR Therapeutics AG
  7. 7AbCellera Biologics
  8. 8Beam Therapeutics
  9. 9Pacific Biosciences Of California
  10. 10Schrodinger
  11. 11Ginkgo Bioworks HoldingsNot disclosed
  12. 12Akoya Biosciences, Inc.Not disclosed
  13. 13Flotek Industries, Inc.Not disclosed
  14. 14Harvard Bioscience, Inc.Not disclosed
  15. 15Maravai Lifesciences HoldingsNot disclosed
  16. 16Perimeter SolutionsNot disclosed
  17. 17Quanterix CorporationNot disclosed
  18. 18Sangamo Therapeutics, Inc.Not disclosed
  19. 19Seres Therapeutics, Inc.Not disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.